title: Polo-like kinase 1 (PLK1) expression is associated with cell proliferative activity and cdc2 expression in malignant lymphoma of the thyroid.
abstract: BACKGROUND
  Polo-like kinase 1 (PLK1) is one of the serine threonine kinases that plays a role in cellular proliferation by activating the CDC25C-CDK1 (cdc2) loop. We recently demonstrated that cdc2 expression is associated with the biological aggressiveness of malignant lymphoma of the thyroid. In this study, we investigated PLK1 expression in thyroid lymphoma in order to elucidate its physiological significance in this disease.
  
  
  METHODS
  We immunohistochemically investigated PLK1 expression in 46 cases of thyroid lymphoma and 10 cases of chronic thyroiditis.
  
  
  RESULTS
  Normal follicular cells did not express PLK1, whereas follicular cells in those in chronic thyroiditis and malignant lymphoma demonstrated a high level of PLK1 expression. In lymphocytes in chronic thyroiditis with strong lymphocyte infiltration, PLK1 was weakly expressed. In malignant lymphoma, PLK1 expression was observed in all cases, but PLK1 was more strongly expressed in cases with high cell proliferative activity and with cdc2 expression.
  
  
  CONCLUSIONS
  These results suggest that PLK1 regulates the cell cycle progression of thyroid lymphoma cells in the G2-M-phase.
authors.affiliation: Department of Surgery, Kuma Hospital, 8-2-35, Shimoyamate-dori, Chuo-ku, Kobe 650-0011, Japan. ito01@kuma-h.or.jp
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Ito
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Yoshida
authors.forename: Fumio
authors.initials: F
authors.lastname: Matsuzuka
authors.forename: Nariaki
authors.initials: N
authors.lastname: Matsuura
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Nakamura
authors.forename: Hirokazu
authors.initials: H
authors.lastname: Nakamine
authors.forename: Kennichi
authors.initials: K
authors.lastname: Kakudo
authors.forename: Kanji
authors.initials: K
authors.lastname: Kuma
authors.forename: Akira
authors.initials: A
authors.lastname: Miyauchi
mesh_terms: D016203:CDC2 Protein Kinase / Q000096:biosynthesis*; D018797:Cell Cycle Proteins; D002455:Cell Division / Q000502:physiology; D006801:Humans; D007150:Immunohistochemistry; D008214:Lymphocytes / Q000276:immunology; D008223:Lymphoma / Q000201:enzymology* / Q000276:immunology / Q000473:pathology; D011494:Protein Kinases / Q000096:biosynthesis*; D017346:Protein Serine-Threonine Kinases; D011518:Proto-Oncogene Proteins; D013964:Thyroid Neoplasms / Q000201:enzymology* / Q000276:immunology / Q000473:pathology; D013967:Thyroiditis, Autoimmune / Q000201:enzymology / Q000276:immunology / Q000473:pathology; D000097869:Polo-Like Kinase 1
chemical_list: D016203:CDC2 Protein Kinase; D018797:Cell Cycle Proteins; D011494:Protein Kinases; D017346:Protein Serine-Threonine Kinases; D011518:Proto-Oncogene Proteins; D000097869:Polo-Like Kinase 1